OMEROS CORP Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments
OMEROS CORP (OMER) reported Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments of -$33.00 thousand for the 12-month period ending 2010-12-31, per its 10-K filed 2012-03-15.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2012-03-15
- OMEROS CORP available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2010 was -$33.00K.
- OMEROS CORP available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2009 was -$34.00K.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month |
|---|---|
| 2010-12-31 | -$33.00K 10-K · filed 2012-03-15 |
| 2009-12-31 | -$34.00K 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |